Article
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.
Nature communications - 12 Mar 2026
Murciano-Goroff Yonina R, Hollebecque Antoine, Heist Rebecca S, Cassier Philippe A, Han Ji-Youn, Kim So Yeon, Sabari Joshua K, Tosi Diego, Sacher Adrian, Burns Timothy F, Shimizu Toshio, Reddy Ammakkanavar Natraj, Spira Alexander, Gomez-Roca Carlos, Patnaik Amita, Cosman Rasha, Bodor J Nicholas, Nagasaka Misako, You Arthur Xintian, McNeely Samuel C, Peter Raimund, Fink Aaron, Chen Aaron, Oxnard Geoffrey R, Willard Melinda D, Kuboki Yasutoshi, Koyama Takafumi
Abstract excerpt
This multicenter, first-in-human Phase 1 study (NCT04956640) evaluated olomorasib (LY3537982), a next-generation KRAS G12C inhibitor designed to enhance target occupancy at low absolute exposures. In total, data from 195 patients are reported: Phase 1a dose escalation (n = 112) assessed olomorasib monotherapy at 50, 100, 150 or 200 mg BID across KRAS G12C-mutant advanced solid tumors; the primary objective was to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.